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We studied the effects of various gangliosides on
in vitro growth of human metastatic melanoma
WM266-4. GD1b, GT1b, and GQ1b inhibited 3H-
thymidine uptake and growth rate of WM266-4
whereas the other gangliosides were ineffective. The
growth inhibition by GD1b, GT1b, and GQ1b was
counteracted by interleukin-8 but not by the other
growth factors. The growth inhibition by ganglio-
sides was not detected in the presence of anti-inter-
leukin-8 antibody. GD1b, GT1b, and GQ1b reduced
the constitutive interleukin-8 secretion and mRNA
levels in WM266-4. Transient transfection showed
that GD1b, GT1b, and GQ1b inhibited the constitu-
tive chloramphenicol acetyltransferase expression
driven by interleukin-8 promoter in WM266-4.
Transfection with a series of 5¢-deleted mutants dem-
onstrated that the sequences between ±98 and ±62 bp
on interleukin-8 promoter may be involved in the
transcriptional repression by these gangliosides.
Cyclic AMP analog dibutyryl cAMP counteracted
GD1b, GT1b, and GQ1b-induced inhibition of inter-
leukin-8 production at the levels of protein secretion,
mRNA expression, and promoter activity. GD1b,
GT1b, and GQ1b reduced cAMP level and protein
kinase A activity in WM266-4. These gangliosides
suppressed adenylate cyclase activity without altering
that of cyclic nucleotide phosphodiesterase in
WM266-4. The data indicate that GD1b, GT1b, and
GQ1b may suppress the growth of melanoma by
inhibiting interleukin-8 production via the inhibition
of adenylate cyclase. Key words: cAMP/ protein kinase
A/ transcription. J Invest Dermatol 117:284±293, 2001
G
angliosides are sialic-acid-containing glycosphingoli-
pids, and are constituents of the plasma membranes of
various cells (Rodden et al, 1991). GM2, GM3,
GD2, and GD3 are major gangliosides in the plasma
membranes of melanoma (Hoon et al, 1988), and
play important roles in the invasion or metastasis of melanoma;
GD2 and GD3 interact with extracellular matrix proteins, such as
®bronectin or type I and IV collagens. GM3 is also involved in the
integrin receptor expression of melanoma (Burns et al, 1988;
Cheresh, 1989; Nakano et al, 1999). Melanoma cell surface GM2
also functions as a target recognition structure for lymphokine-
activated killer cells (Hoon et al, 1989). Some gangliosides are also
shed into the extracellular environment, and exhibit physiologic
functions (Hakomori, 1990); GM2 and GD2 enhance the
proliferative response to interleukin-2 (IL-2) of lymph node
lymphocytes from melanoma patients whereas GM3 and GD3
inhibit the response (Hoon et al, 1988). The effects of exogenous
gangliosides on the growth of melanoma per se, however, have not
been precisely examined. Exogenous gangliosides interact with
plasma membranes and modulate transmembrane signaling path-
ways, and thus regulate cell growth and differentiation (Hakomori,
1990). In particular gangliosides regulate 3¢,5¢-adenosine cyclic
monophosphate (cAMP) related signaling pathways (Partington and
Daly, 1979; Davis and Daly, 1980; Yates et al, 1989; Depauw et al,
1990). Cyclic AMP binds to protein kinase A (PKA) and thus
upregulates the activity of PKA to phosphorylate proteins at the
serine/threonine position (Garcia et al, 1999). Intracellular cAMP
level is controlled by cAMP-synthesizing adenylate cyclase (AC)
and by cAMP-hydrolyzing cyclic nucleotide phosphodiesterase
(PDE). It is reported that gangliosides modulate the activities of AC
and PDE; mixed brain gangliosides enhanced AC and PDE
activities from rat cerebral cortex (Partington and Daly, 1979; Davis
and Daly, 1980). It is thus plausible that exogenous gangliosides
may regulate the growth of melanoma by modulating signaling
pathways including those related to cAMP. Previous studies
support that metastatic melanoma constitutively produces a variety
of growth factors, such as IL-8, melanocyte growth stimulatory
activity/growth-regulated protein a (GRO-a), etc., and thus
proliferates through the autocrine growth factor loop in serum-free
conditions (Herlyn, 1990). It is thus hypothesized that gangliosides
may alter the growth of metastatic melanoma by modulating its
autocrine growth factor production.
In this study, we aimed to examine the growth-regulatory effects
of various gangliosides in human metastatic melanoma WM266-4,
focusing on their effects on autocrine growth factor production.
We have found that GD1b, GT1b, and GQ1b suppressed the
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growth of WM266-4 by inhibiting IL-8 production. We further
examined the involvement of the cAMP-related signaling pathway
in the ganglioside-induced inhibition of IL-8 production.
MATERIALS AND METHODS
Cell line and maintenance Metastatic melanoma cell line WM266-4
obtained from a female patient was purchased from Dainippon
Pharmaceutical (Osaka, Japan), and was cultured in Dulbecco's modi®ed
Eagle's medium (Gibco-BRL, Grand Island, NY) supplemented with
10% fetal bovine serum (Gibco-BRL), 1% nonessential amino acids,
1 mM sodium pyruvate (ICN Biomedicals, Aurora, OH), and 100 U per
ml penicillin G, 100 mg per ml streptomycin, 0.25 mg per ml
amphotericin B (Gibco-BRL).
Reagents Gangliosides GM1, GM2, GM3, GD1a, GD1b, GD2, GD3,
GT1b, and GQ1b were purchased from Sigma Chemical (St. Louis,
MO). N-acetylneuraminic acid was from Dextra Laboratories (Reading,
U.K.). Ceramide was from Research Biochemicals International (Natick,
MA). Dibutyryl cAMP (Bt2cAMP), dibutyryl 3¢,5¢-guanosine cyclic
monophosphate (Bt2cGMP), forskolin, N-[2-((p-bromocinnamyl)-
aminoethyl]-5-isoquinolinesulfonamide (H-89), and 1-oleoyl-2-acetyl-sn-
glycerol (OAG) were obtained from Calbiochem (La Jolla, CA). These
agents were dissolved in dimethylsulfoxide as 10 mM stock solution and
were kept dark until used. Recombinant human IL-8 was from Sigma.
Recombinant human GRO-a_was from Pepro Tech (London, U.K.).
Mouse IgG antihuman IL-8 was from BioSource International
(Camarillo, CA). Human recombinant platelet-derived growth factor AB
(PDGF-AB) was from Carbiochem-Novabiochem (San Diego, CA).
Recombinant human IL-6 was from Boehringer Mannheim
(Indianapolis, IN). Recombinant human basic ®broblast growth factor
(bFGF) was from Becton Dickinson (San Jose, CA). Control mouse IgG
was from Dako (Carpinteria, CA).
3H-thymidine assays WM266-4 cells were plated at 5 3 103 cells
per well in triplicate into ¯at-bottomed 96-well plates in 100 ml per well
of culture medium, and adhered for 18 h. The medium was discarded
and the cells were washed with phosphate-buffered saline three times,
and then incubated with various gangliosides and/or recombinant
cytokines at the indicated concentrations for 40 h in 100 ml per well of
serum-free Dulbecco's modi®ed Eagle's medium without
supplementation of growth factors to avoid contamination of gangliosides
in the serum. Then 0.5 mCi per well of 3H-thymidine (Amersham,
Arlington Heights, IL) was added and the cells were incubated for an
additional 8 h prior to harvest. The incorporation of 3H-thymidine was
assayed by liquid scintillation.
Growth assays WM266-4 cells were plated in triplicate at 104 cells
per well into 24-well plates, adhered for 18 h, washed, and incubated
with various gangliosides at the indicated concentrations in 1 ml per well
of serum-free, growth-factor-free medium. Growth studies were carried
out for 8 d with medium changes every 2 d. Cells were counted at
speci®ed days by Coulter counter.
Measurement of cytokines To measure cytokine secretion, WM266-
4 cells were plated in triplicate at 5 3 104 per well into 24-well plates,
adhered for 18 h, washed, and incubated with various gangliosides at the
indicated concentrations in 1 ml per well of serum-free medium for
24 h, and the culture supernatants were harvested and stored at ±70°C
until used. The activity of IL-6 and IL-8 in the supernatants was
measured by enzyme-linked immunosorbent assay (ELISA) kits
(Biosource), that of GRO-a and bFGF was measured by ELISA kits (R
& D Systems, Minneapolis, MN), and that of PDGF-AB was measured
by ELISA kit (Genzyme Techne, Minneapolis, MN), according to the
manufacturers' instructions. The sensitivity of the assay for IL-6, IL-8,
GRO-a, bFGF, or PDGF-AB was 2, 5, 10, 0.5, or 8.4 pg per ml,
respectively.
For the analysis of cytokine mRNA expression, reverse transcriptase
polymerase chain reaction (RT-PCR) was performed. WM266-4 cells
were incubated with various gangliosides in 24-well plates as above for
8 h, and were harvested by trypsinization. Total RNA was extracted
from the harvested cells and was reverse transcribed as described
previously (Kanda, 1999). PCR conditions are described elsewhere
(Kanda, 1999). The following primer sequences were used: IL-8, 5¢-
ATG ACT TCC AAG CTG GCC GTG GCT-3¢ and 5¢-TCT CAG
CCC TCT TCA AAA ACT TCT C-3¢ (product size 289 bp) (Lupetti
et al, 1996); b-actin, 5¢-GGG TCA GAA GGA TTC CTA TG-3¢ and
5¢-GGT CTC AAA CAT GAT CTG GG-3¢ (product size 268 bp)
(Kanda, 1999). The PCR products were analyzed by electrophoresis on
2.5% agarose gels and stained with ethidium bromide. The band intensity
of the PCR product for IL-8 was determined by densitometry (Hoefer
Scienti®c Instruments, San Francisco, CA) and the ratio relative to b-
actin product was calculated.
Plasmids, transfection, and chloramphenicol acetyl transferase
(CAT) expression pCAT3-basic vector carrying two SV40 polyA
signals, one downstream of the CAT reporter gene and the other
upstream of the multicloning site, was purchased from Promega
(Madison, WI). The EcoRI-HindIII fragment of the genomic IL-8 DNA,
which spans nucleotides ±1481 to +44 bp relative to the transcriptional
start site (Mukaida et al, 1989), was subcloned into PUC19, treated with
appropriate restriction endonucleases, and further subcloned into
pCAT3-basic vector as described previously (Dorn and Derse, 1988;
Mukaida et al, 1989). Transfection of melanoma cells was carried out by
the calcium coprecipitation method using CellPhect transfection kit
(Amersham) according to the manufacturer's instruction. Brie¯y, 1 d
before the experiment, con¯uent cultures of melanoma cells were
trypsinized, and cells were seeded at 1 3 106 cells per 10 cm dish and
incubated overnight at 37°C. The cultures were replenished with fresh
medium and kept at 37°C for 4 h before transfection. The cells were
incubated with the DNA-calcium precipitate containing 10 mg of IL-8
promoter-CAT reporter plasmid for an additional 4 h. The cultures were
then glycerol shocked and replenished with fresh medium. After 3 h, the
cells were trypsinized and subdivided into 24-well plates at 5 3 104 cells
per well and incubated in 1 ml per well of culture medium for 18 h.
This procedure eliminates differences in transfection ef®ciency as the
same construct is used for transfection of separate cultures. Then the
medium was discarded and the cells were washed with phosphate-
buffered saline and incubated with various gangliosides at indicated
concentrations in serum-free medium. After 24 h, the cells were
harvested and lyzed by three freeze/thaw cycles. The cell lysate was
centrifuged and supernatant was assayed for CAT expression by CAT-
ELISA (Roche Diagnostics, Tokyo, Japan) according to the
manufacturer's instruction. Total protein amount was measured with a
Bio-Rad protein assay kit. The expression of various CAT plasmids was
presented as picograms CAT enzyme synthesized per microgram total
protein. pCAT3-control vector (Promega) containing SV40 early
promoter and enhancer sequences was used as a positive control, and
promoterless pCAT3-basic vector was used as a negative control.
Measurement of cAMP amount WM266-4 cells were plated at
5 3 104 cells per well in 24-well plates, adhered for 18 h, washed, and
incubated with gangliosides in 1 ml per well of serum-free, growth-
factor-free medium for 30 min. The medium was discarded, and the cells
were lyzed with acetate buffer (pH 5.8) containing 0.25%
dodecyltrimethylammonium bromide. The cAMP amount in the lysate
was measured with an ELISA kit from Amersham according to the
manufacturer's instruction. The sensitivity of the assay was 12 fmol per
assay well. The intracellular cAMP level was presented as pmol per 106
cells.
Measurement of PDE activity WM266-4 cells were cultured with
gangliosides for 30 min in 24-well plates as described above, and were
lyzed in the buffer containing 20 mM Tris-HCl (pH 7.4), 1 mM
ethylenediamine tetraacetic acid, 1 mg per ml aprotinin, 1 mg per ml
pepstatin, 1 mg per ml leupeptin, 15 mM benzamidine, and 3.75 mM b-
mercaptoethanol. PDE activity of the cell lysate was assayed as described
previously (Epstein et al, 1980; Robicsek et al, 1991) using 1 mM
[2,8-3H] cAMP (30 Ci per mmol) (Amersham) as a substrate. The assays
were performed in 40 mM Tris-HCl (®nal pH 8.0), 10 mM MgCl2 at
37°C for 10 min, and PDE activity was presented as pmol cAMP
hydrolyzed per min per mg protein.
Measurement of AC activity The lysate of WM266-4 cells was
centrifuged at 23,600g for 10 min. The pellet was used as a particulate
fraction for AC assays as described previously (Salomon et al, 1974; Choi
et al, 1992). The AC activity of the fraction was measured at 37°C for
10 min in 20 mM Tris-HCl (pH 7.4), 1 mM [a-32P] ATP (30 Ci per
mmol) (Amersham), 1 mM [3H] cAMP, 1 mM 3-isobutyl-1-
methylxanthine, 5 mM MgCl2, 0.2 mM ethyleneglycol-bis(b-aminoethyl
ether)-N,N,N¢,N¢-tetraacetic acid, 20 mM creatine phosphate, and 100
units per ml creatine phosphokinase. AC activity was presented as pmol
cAMP formed per min per mg protein.
Assays of PKA The lysate of WM266-4 cells was centrifuged at
23,600g for 10 min. The supernatant was assayed for the activity of PKA
by an ELISA kit (Medical and Biological Laboratories, Nagoya, Japan),
utilizing synthetic peptide-precoated microtiter plates and a monoclonal
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antibody recognizing the phosphorylated form of the peptide. The PKA
activity was expressed as the optical density at 492 nm.
Statistical analyses One-way analysis of variance with Dunnet's
multiple comparison test was used for the data in Figs 1(a, b) and 3(a).
One-way analysis of variance with Scheffe's multiple comparison test was
used for the data in Figs 1(c), 2, 3(b), 5±8, and 9 and Table I.
RESULTS
The effects of various gangliosides on the growth of
melanoma cells As shown in Fig 1(a), GD1b, GT1b, and
GQ1b dose-dependently inhibited 3H-thymidine uptake of
WM266-4 whereas the other gangliosides were ineffective;
percentage inhibition versus control by 1 mM of GD1b, GT1b, or
GQ1b was 49%, 48%, or 45%, respectively. The viability of
WM266-4, which was examined by trypan blue dye exclusion test,
was not altered by these gangliosides; the viability was >95% in
control and GD1b-, GT1b-, or GQ1b-treated cells. The 3H-
thymidine uptake of WM266-4 was not altered by the other
gangliosides, GM1, GM2, GM3, GD1a, GD2, GD3 (Fig 1a), or
ceramide, or N-acetylneuraminic acid (data not shown). As 1 mM
of GD1b, GT1b, and GQ1b appeared to be the optimal
concentration for growth inhibition, this concentration was used
in the further experiments. The results in growth assays by counting
cell number correlated with those in 3H-thymidine assays (Fig 1b);
1 mM of GD1b, GT1b, and GQ1b signi®cantly suppressed the
increase of cell number in WM266-4 at 2, 4, 6, and 8 d of exposure
whereas the other gangliosides did not alter the growth rate. The
percentage decrease in cell number at 8 d was 50%, 45%, or 52% by
GD1b, GT1b, or GQ1b compared to controls. The doubling time
in controls was 60 h whereas that in GD1b-, GT1b-, or GQ1b-
treated cells was 122 h, 115 h, or 127 h, respectively. These results
indicate that GD1b, GT1b, or GQ1b may directly inhibit the
proliferation of WM266-4.
The combination of more than two different gangliosides among
GD1b, GT1b, and GQ1b resulted in neither additive nor
synergistic inhibition on 3H-thymidine uptake (Fig 1c). Similar
results were obtained in growth assays with direct cell counting
(data not shown). These indicate that the mechanism for growth
inhibition may be common among GD1b, GT1b, and GQ1b, and
that the response in WM266-4 may be saturated by an optimal
concentration of either ganglioside.
IL-8-induced reversal from growth inhibition by GD1b,
GT1b, and GQ1b As metastatic melanoma cells constitutively
produce various growth factors and autonomously proliferate via
such growth factors, it is indicated that the growth-inhibitory
effects of GD1b, GT1b, and GQ1b may be mediated by inhibiting
the autocrine growth factor production in WM266-4. To identify
the cytokine(s) that may be involved in the growth inhibition by
these gangliosides various cytokines reported as autocrine growth
factors of melanoma (Herlyn, 1990) were added to WM266-4 cells
cultured with the gangliosides, and their in¯uence on GD1b-,
GT1b-, or GQ1b-induced growth inhibition was examined.
Among various cytokines, only IL-8 overcame the GD1b-
induced inhibition of 3H-thymidine uptake in WM266-4
(Fig 2). When endogenous IL-8 activity was neutralized by anti-
IL-8 antibody, the 3H-thymidine uptake of WM266-4 was reduced
by 65% compared to control, indicating that IL-8 may act as a main
autocrine growth factor in WM266-4. In the presence of anti-IL-8,
GD1b did not further reduce the 3H-thymidine uptake of
WM266-4. The GT1b- or GQ1b-induced inhibition of 3H-
thymidine uptake was also overcome by IL-8, and GT1b or GQ1b
did not further reduce the 3H-thymidine uptake of WM266-4 in
the presence of anti-IL-8 (data not shown). Similar results were
obtained in growth assays with direct cell counting (data not
shown). These results suggest that the growth-inhibitory effect of
GD1b, GT1b, and GQ1b may be mediated via IL-8 in WM266-4.
We then examined if GD1b, GT1b, or GQ1b may alter IL-8
production in WM266-4.
The effects of GD1b, GT1b, and GQ1b on IL-8 production
in melanoma WM266-4 constitutively secreted a large amount
of IL-8 (8.2 ng by 5 3 104 cells). GD1b, GT1b, or GQ1b dose-
Figure 1. The dose-dependency for the effects of various
gangliosides on the proliferation of melanoma. (a) WM266-4 cells
were plated, adhered, then washed, and incubated with various
gangliosides at the indicated concentrations as described in Materials and
Methods. After 40 h, the cells were pulsed with 3H-thymidine for an
additional 8 h before harvesting. The data are shown as percentage versus
3H-thymidine uptake of control cultures with medium alone. Results
represent the mean 6 SEM of four separate experiments. *p < 0.05 vs
control cultures by analysis of variance with Dunnet's multiple
comparison test. The 3H-thymidine uptake in control cultures was (mean
6 SEM, n = 4) 18,536 6 1523 cpm. (b) WM266-4 cells were plated at
1 3 104 cells per well in 24-well plates; after 18 h the medium was
replaced with serum-free medium and various gangliosides were added at
1 mM, and the cells were cultured for additional 8 d with medium
change every 2 d. Cell number was counted at the indicated time points.
*p < 0.05 vs control cultures by analysis of variance with Dunnet's
multiple comparison test. (c) WM266-4 cells were cultured with the
indicated combination of GD1b, GT1b, or GQ1b (each 1 mM), and 3H-
thymidine uptake was analyzed as described above. *p < 0.05 vs control
cultures by analysis of variance with Scheffe's multiple comparison test.
The 3H-thymidine uptake in control cultures was (mean 6 SEM, n = 4)
19,213 6 1641 cpm.
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dependently inhibited IL-8 secretion in WM266-4; percentage
inhibition by 1 mM of GD1b, GT1b, or GQ1b was 68%, 67%, or
62%, respectively, compared to controls (Fig 3a). The
combination of more than two different gangliosides among
GD1b, GT1b, and GQ1b resulted in neither additive nor
synergistic inhibition on the IL-8 secretion (Fig 3b), which
correlated with the ganglioside-induced inhibition of 3H-
thymidine uptake (Fig 1c). The other gangliosides (Fig 3a),
ceramide, or N-acetylneuraminic acid (data not shown) did not
alter the IL-8 secretion in WM266-4. Though WM266-4
constitutively secreted a large amount of GRO-a, GD1b, GT1b,
GQ1b (Table I), or the other gangliosides, or ceramide, N-
acetylneuraminic acid (data not shown) did not alter the secretion
of GRO-a. The secretion of PDGF-AB, bFGF, and IL-6 was
lower than that of IL-8 or GRO-a, and was not altered by any
gangliosides.
We then analyzed if IL-8 mRNA level in WM266-4 may be
altered by GD1b, GT1b, or GQ1b. As analyzed by RT-PCR
(Fig 4a, b), WM266-4 constitutively expressed IL-8 mRNA, and
the mRNA level was reduced by GD1b, GT1b, and GQ1b. GM1
(Fig 4) or the other gangliosides, GM2, GM3, GD1a, GD2, GD3,
or ceramide, N-acetylneuraminic acid (data not shown) did not
alter the steady-state IL-8 mRNA level in WM266-4. Thus the
inhibitory effects of GD1b, GT1b, and GQ1b on the IL-8 mRNA
level closely correlated with those on IL-8 protein secretion
(Fig 3), suggesting the pretranslational inhibition. We then exam-
ined if GD1b, GT1b, and GQ1b may exert their effects at the
transcriptional level by analyzing the effects of these gangliosides on
the activity of IL-8 promoter.
The effects of GD1b, GT1b, and GQ1b on CAT expression
driven by IL-8 promoter WM266-4 cells were transiently
transfected with plasmid containing a full-length IL-8 promoter
Figure 3. Dose-dependency for the effects of various gangliosides
on IL-8 secretion in melanoma. (a) WM266-4 cells were plated,
adhered, then washed, and cultured with the indicated concentrations of
gangliosides. After 24 h, IL-8 activity in culture supernatants was
analyzed by ELISA. The data are shown as percentage versus IL-8
secretion in control cultures with medium alone. Results represent the
mean 6 SEM of four separate experiments. *p < 0.05 vs control cultures
by analysis of variance with Dunnet's multiple comparison test. The IL-8
secretion in control cultures was (mean 6 SEM, n = 4) 8213 6 914 pg
per ml. (b) WM266-4 cells were cultured with the indicated
combination of GD1b, GT1b, or GQ1b (each 1 mM) as described
above. *p < 0.05 vs control cultures by analysis of variance with Scheffe's
multiple comparison test. The IL-8 secretion in control cultures was
(mean 6 SEM, n = 4) 8194 6 895 pg per ml.
Figure 2. Cytokine-induced recovery from the inhibitory effect of
GD1b on the 3H-thymidine uptake of melanoma. WM266-4 cells
were plated, washed, and cultured in the presence or absence of GD1b
(1 mM) with or without various cytokines (each 5 ng per ml) before
examining 3H-thymidine uptake as described in the legend to Fig 1. In
some experiments, the culture was performed in the presence of mouse
anti-IL-8 antibody or control mouse IgG (each 10 mg per ml). The data
are shown as percentage versus 3H-thymidine uptake of control cultures
with medium alone. Results represent the mean 6 SEM of four separate
experiments. *p < 0.05 vs control cultures and ²p < 0.05 vs cultures of
GD1b alone, by analysis of variance with Scheffe's multiple comparison
test. The 3H-thymidine uptake in control cultures was (mean 6 SEM,
n = 4) 18,289 6 1626 cpm.
Table I. The effects of GD1b, GT1b, and GQ1b on the
secretion of cytokines other than IL-8 in melanomaa
Conditions
GRO-a
(pg per ml)
PDGF-AB
(pg per ml)
bFGF
(pg per ml)
IL-6
(pg per ml)
Control 8124 6 913b 401 6 45 61 6 7 310 6 31
GD1b 8245 6 987 392 6 39 59 6 6 312 6 29
GT1b 8231 6 967 412 6 41 62 6 8 299 6 31
GQ1b 7912 6 893 402 6 40 61 6 7 315 6 36
aWM266-4 cells were plated, washed, and incubated with GD1b, GT1b, or
GQ1b (each 1 mM) for 24 h as described in Materials and Methods. The cytokine
activity in the culture supernatants was analyzed by ELISA.
bThe results are shown as the mean 6 SEM of four separate experiments.
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(±1481 to +44 bp) driving CAT reporter gene (±1481-CAT), and
the promoter activity was assessed by the expression of CAT
enzyme. Though it is known that IL-8 promoter activity is
upregulated by IL-1 or tumor necrosis factor a (Mukaida et al,
1989), WM266-4 cells transfected with ±1481-CAT showed
considerable levels of CAT expression driven by the IL-8
promoter (66.5 pg CAT per mg protein) even in the
unstimulated state. GD1b, GT1b, or GQ1b inhibited the
constitutive activity of the full-length IL-8 promoter by 68%,
67%, or 65%, respectively, compared to controls (Fig 5a). The
other gangliosides (Fig 5a), ceramide, or N-acetylneuraminic acid
(data not shown) did not alter the constitutive activity of the full-
length IL-8 promoter. These results in IL-8 promoter activity are
consistent with those in mRNA level (Fig 4) and protein secretion
(Fig 3). It is thus suggested that GD1b, GT1b, and GQ1b may
suppress IL-8 production at the transcriptional level, although post-
transcriptional suppression is also implicated. To characterize the
DNA sequences involved in ganglioside-induced transcriptional
repression on IL-8 gene, we used CAT expression plasmids linked
to serially 5¢-deleted IL-8 promoters, and compared the effects of
gangliosides on the activities of the deleted promoters. In
transfected WM266-4 cells, the constitutive promoter activity of
±1481-CAT, ±546-CAT, or ±272-CAT was repressed by GD1b,
GT1b, and GQ1b (Fig 5b). The constitutive promoter activity of
±98-CAT was reduced compared to that of ±1481, ±546 or ±272-
CAT, indicating that the sequences between ±272 and ±98 bp may
partially contribute to the constitutive promoter activity. The
promoter activity of ±98-CAT was still repressed by GD1b, GT1b,
and GQ1b, however; percentage inhibition by GD1b, GT1b, or
GQ1b was 71%, 67%, or 67%, respectively. These results indicate
that the sequences up to ±98 bp may be dispensable for the
transcriptional repression by these gangliosides. When WM266-4
was transfected with ±62-CAT, the constitutive promoter activity
was further reduced, and was not at all repressed by GD1b, GT1b,
or GQ1b. These results suggest that the sequences between ±98 and
±62 bp may partially direct the constitutive IL-8 transcription and
may be mainly involved in GD1b-, GT1b-, and GQ1b-induced
transcriptional repression. The other gangliosides, ceramide, or N-
acetylneuraminic acid did not alter the constitutive activity of
serially 5¢-deleted IL-8 promoters in transfected WM266-4 cells
(data not shown).
Cyclic AMP-induced reversal from GD1b-, GT1b-, and
GQ1b-induced inhibition on IL-8 production It is known
that gangliosides modulate a variety of intracellular signaling
pathways (Hakomori, 1990). Thus GD1b, GT1b and GQ1b may
repress the constitutive IL-8 production by inhibiting certain
Figure 4. RT-PCR analysis for the effects of gangliosides on
steady-state IL-8 mRNA level in melanoma. WM266-4 cells were
plated, adhered, then washed, and cultured with the indicated
gangliosides (each 1 mM). After 8 h, RNA was extracted from the
harvested cells, and RT-PCR was performed. RT-PCR products were
analyzed by electrophoresis (a) and the intensity of the products was
analyzed by densitometry (b). The data represent four separate
experiments.
Figure 5. The inhibitory effects of GD1b,
GT1b, and GQ1b on full-length IL-8
promoter activity in melanoma and the
in¯uence of 5¢-deletion on the ganglioside-
induced inhibition of IL-8 promoter activity.
(a) WM266-4 cells were transiently transfected
with 1481 bp IL-8 promoter-CAT reporter
construct and cultured with various gangliosides
(each 1 mM). The IL-8 promoter activity was
assessed by CAT expression of the cell lysate. The
data are shown as percentage versus CAT
expression in control cultures with medium alone.
The CAT expression in control cultures was
(mean 6 SEM, n = 4) 66.5 6 6.9 pg CAT per
mg protein. (b) WM266-4 cells were transfected
with CAT reporter vectors into which various 5¢-
deleted IL-8 promoters were cloned. After
transfection, the cells were incubated with or
without GD1b, GT1b, or GQ1b (each 1 mM),
and CAT expression was analyzed. The CAT
expression by pCAT3-control vector was
130 6 11 pg CAT per mg protein, and that by
promoterless pCAT3-basic vector was less than
detectable level. Results represent the mean 6
SEM of four separate experiments. *p < 0.05 vs
control cultures, by analysis of variance with
Scheffe's multiple comparison test.
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signaling pathways involved in the production. It is reported that
activation of the PKA- or protein-kinase-C-dependent signaling
pathway induces IL-8 transcription (Mukaida et al, 1989). To
identify the target signal for the ganglioside-induced repression, we
examined whether several signal-inducers may counteract the
ganglioside-induced repression of IL-8 production. The signal-
inducers were cAMP analog Bt2cAMP, which activates PKA,
cGMP analog Bt2cGMP activating protein kinase G, and
diacylglycerol analog OAG activating protein kinase C. As shown
in Fig 6, the signal-inducers were added at low concentrations that
did not alter the constitutive IL-8 production with medium alone.
Bt2cAMP reversed the GD1b-induced repression of IL-8 secretion
(Fig 6a) and of IL-8 promoter (±98-CAT) activity (Fig 6b). The
GD1b-induced inhibition of IL-8 production was also reversed by
cAMP-elevating agents, AC activator forskolin (1 mM), or PDE
inhibitor 3-isobutyl-1-methylxanthine (50 mM) (data not shown).
In contrast, GD1b-induced inhibition on IL-8 secretion and IL-8
promoter activity was not counteracted by Bt2cGMP or OAG.
When the endogenous PKA activity in WM266-4 was blocked by
speci®c PKA inhibitor H-89, IL-8 secretion (Fig 6a) and promoter
activity (Fig 6b) was reduced by 78% and 70%, respectively,
compared to controls, suggesting that the cAMP±PKA pathway
may contribute to the constitutive IL-8 transcription in WM266-4.
In the presence of H-89, GD1b did not further reduce IL-8
secretion and promoter activity, indicating that the cAMP±PKA
pathway may be the main target for the GD1b-mediated inhibition.
GT1b- or GQ1b-induced inhibition of IL-8 secretion and
promoter activity was reversed by Bt2cAMP, forskolin, and 3-
isobutyl-1-methylxanthine, but not by Bt2cGMP or OAG (data
not shown). The cAMP analog or cAMP-elevating agents also
reversed the GD1b-, GT1b-, and GQ1b-induced reduction of IL-8
mRNA level as examined by RT-PCR (data not shown). These
results suggest that GD1b-, GT1b-, and GQ1b-induced inhibition
of IL-8 production may be attributable to inhibition of the cAMP±
PKA signaling pathway. We then examined whether these
gangliosides may reduce cAMP level or PKA activity in
WM266-4.
The effects of gangliosides on cAMP level and the activities
of PKA, AC, and PDE in WM266-4 As shown in Fig 7(a),
Figure 6. The cAMP-mediated reversal of
the GD1b-induced inhibition on IL-8
secretion and IL-8 promoter activity. (a)
WM266-4 cells were preincubated with or
without 50 mM Bt2cAMP, 50 mM Bt2cGMP,
100 ng per ml OAG, or 0.1 mM H-89 for
30 min, and then GD1b (1 mM) was added to the
culture. After 24 h, IL-8 secretion was analyzed
by ELISA. (b) WM266-4 cells were transfected
with 98 bp IL-8 promoter-CAT reporter
construct (±98-CAT) and preincubated as above;
then GD1b (1 mM) was added to the culture.
After 24 h, IL-8 promoter activity was assessed by
CAT expression of the cell lysate. The data are
shown as percentage versus the values in control
cultures with medium alone, and represent the
mean 6 SEM of four separate experiments. The
IL-8 secretion or CAT expression in control
cultures was (mean 6 SEM, n = 4)
8132 6 793 pg per ml or 42.5 6 4.5 pg CAT
per mg protein, respectively. *p < 0.05 vs control
cultures with medium alone and ²p < 0.05 vs
cultures with GD1b alone, by analysis of variance
with Scheffe's multiple comparison test.
Figure 7. The effects of gangliosides on
cAMP level and PKA activity in melanoma.
(a) cAMP level; (b) PKA activity. WM266-4 cells
were incubated with the indicated gangliosides
(each 1 mM) for 30 min. The cells were then
lyzed and assayed for cAMP amount and PKA
activity. The data are the mean 6 SEM of four
separate experiments. *p < 0.05 vs control
cultures, by analysis of variance with Scheffe's
multiple comparison test.
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the treatment with GD1b, GT1b, or GQ1b reduced the cAMP
level in WM266-4 by 76.5%, 76%, or 77%, respectively, compared
to control. The treatment with GD1b, GT1b, or GQ1b also
resulted in a reduction of PKA activity (Fig 7b), which correlated
with that of cAMP level (Fig 7a). In contrast, the other
gangliosides (Fig 7) or ceramide, N-acetylneuraminic acid (data
not shown) did not alter cAMP level or PKA activity. As the
decrease of cAMP level can be mediated by the inhibition of AC
and/or stimulation of PDE, we examined if GD1b, GT1b, and
GQ1b may alter AC and/or PDE activity. As shown in Fig 8(a),
GD1b, GT1b, or GQ1b reduced AC activity in WM266-4 by
87%, 85%, or 86%, respectively, compared to control, whereas the
other gangliosides (Fig 8a) or ceramide, N-acetylneuraminic acid
(data not shown) were ineffective. None of the gangliosides
(Fig 8b), ceramide, or N-acetylneuraminic acid (data not shown)
altered PDE activity. When GD1b was directly added to the
reaction mixture of AC assays, the AC activity was inhibited, and
AC stimulator forskolin reversed the inhibitory effect of GD1b
(Fig 9). Similar results were obtained when GT1b or GQ1b was
used instead of GD1b (data not shown). These results suggest that
GD1b, GT1b, and GQ1b may suppress AC activity without
altering that of PDE and thus reduce cAMP level in WM266-4.
The reduction of cAMP may downregulate the constitutive PKA
activity, which may result in the repression of IL-8 production and
of IL-8-dependent growth in WM266-4.
DISCUSSION
This study demonstrated that gangliosides GD1b, GT1b, and
GQ1b suppressed the growth of melanoma by inhibiting IL-8
production at transcriptional level. The inhibition of IL-8
transcription was mediated by inhibiting AC and thus reducing
intracellular cAMP level and PKA activity. AC is mostly associated
with plasma membranes (Iyengar, 1993). Transmembrane receptors
for certain hormones, neurotransmitters, or other stimuli are
coupled to AC catalytic domains via guanine nucleotide-binding
proteins (G-proteins), and the ligand-binding to the receptor
activates AC catalyst via G-protein (Iyengar, 1993). Gangliosides
are known to modulate AC activity by several different mechanisms
(Partington and Daly, 1979; Whetton et al, 1983; Dacremont et al,
1984; Berry-Kravis and Dawson, 1985; Saito et al, 1995; Wu et al,
1996), and the effects of gangliosides on AC vary with ganglioside
species or concentrations, target cell types, and receptor classes (Wu
et al, 1996). GD1b, GT1b, and GQ1b suppressed the basal AC
activity in melanoma without any stimuli, and the suppression was
reversed by AC catalyst stimulator forskolin (Fig 9). According to
these results, it is most plausible that these gangliosides may directly
inhibit the activity of AC catalysts. GD1b, GT1b, and GQ1b
commonly contain the structure NeuAc(2 ® 8)NeuAc attached to
the internal galactose (Svennerholm, 1963), indicating that this
Figure 8. The effects of various gangliosides
on AC and PDE activity in melanoma. (a)
AC; (b) PDE activity. WM266-4 cells were
incubated with the indicated gangliosides (each
1 mM) for 30 min. The cells were then harvested,
lyzed, and assayed for AC and PDE activities. The
data are the mean 6 SEM of four separate
experiments. *p < 0.05 vs control cultures, by
analysis of variance with Scheffe's multiple
comparison test.
Figure 9. The inhibition of AC activity by direct addition of
GD1b to the assay, and forskolin-mediated reversal of the
inhibition. The particulate fraction of WM266-4 cells was assayed for
AC activity in the presence or absence of GD1b (1 mM) with or without
0.1 or 1 mM forskolin. The data are the mean 6 SEM of four separate
experiments. *p < 0.05 vs control cultures with medium alone and ²p
< 0.05 vs cultures with GD1b alone, by analysis of variance with
Scheffe's multiple comparison test.
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structure may be required for the interaction with AC catalysts.
The second possible mechanism is that GD1b, GT1b, or GQ1b
bind to Ca2+-binding protein, calmodulin in the plasma membrane
of WM266-4, and thus antagonize the function of calmodulin to
activate AC. Gangliosides are known to bind to calmodulin in the
presence of Ca2+ (Higashi et al, 1992). It is also reported that Ca2+±
calmodulin complex stimulates AC types 1 and 3 (Iyengar, 1993)
and that the dissociation of calmodulin from the particulate fraction
of mouse melanoma B16 abolished about 40% of its basal AC
activity (MacNeil et al, 1984). The third possible mechanism is that
the incorporation of GD1b, GT1b, or GQ1b into membranes may
decrease the ¯uidity of the lipid microenvironment surrounding
AC, which may lead to a decrease in AC activity. A close
relationship between lipid ¯uidity and AC activity has been
reported (Whetton et al, 1984; Depauw et al, 1990; Iyengar, 1993).
The fourth possible mechanism is that gangliosides may modulate
the receptors for certain endogenous AC agonists. Melanoma cells
constitutively produce AC agonists such as prostaglandins (Denkert
et al, 2001; Mohammed et al, 2001), though at low levels, and thus
such endogenous AC agonists may contribute to the constitutive
AC activity. GD1b, GT1b, or GQ1b may interact with the
receptors for such endogenous AC agonists, and may change their
conformation, which may inhibit the coupling of receptors to G-
protein stimulatory subunits or induce the coupling to G-protein
inhibitory subunits, and/or reduce the ligand-binding activity of
the receptors (Ucer and Engel, 1981; Kielczynski et al, 1991; 1994;
Morii and Watanabe, 1993). The ®fth possible mechanism is the
direct interaction of gangliosides with the endogenous AC agonists,
which may interfere with their binding to the receptors (Mullin et
al, 1976). It has recently been reported that exogenous gangliosides
are incorporated into detergent-insoluble glycosphingolipid-en-
riched membrane microdomains, termed lipid rafts (Simons et al,
1999). Lipid rafts are enriched in signal transducers, such as
glycosylphosphatidylinositol-anchored proteins, Src-family kinases,
and G-proteins. The external stimuli to glycosphingolipids in the
rafts are converted by the above-mentioned transducers to
intracellular signals, such as protein phosphorylation (Hakomori et
al, 1998). Thus exogenous gangliosides, incorporated into the rafts,
may alter the organization of raft lipid and protein components, and
modulate raft-dependent signal transduction (Prinetti et al, 1999;
Simons et al, 1999). A recent study shows that AC catalysts and G-
protein stimulatory subunits are colocalized with caveolins, integral
membrane proteins, and compartmentalized in caveolae, plasma
membrane invaginations, which are speci®c forms of rafts
(Schwencke et al, 1999). Thus, as the sixth possible mechanism
for the inhibition of AC, it is indicated that caveola-incorporated
GD1b, GT1b, or GQ1b may disrupt the assembly of signaling
complex, caveolin, G-protein, and AC catalyst, which may
resultantly reduce the activity of AC.
The regulatory effects of cAMP on IL-8 production vary with
the cell types: cAMP-elevating agents like prostaglandin E2 or
forskolin enhanced IL-8 production in human colonic epithelial
cells (Yu and Chadee, 1998), peripheral blood mononuclear cells
(Mukaida et al, 1989), and synovial ®broblasts (Agro et al, 1996),
but did not alter that in human alveolar macrophages (Standiford et
al, 1992) and polymorphonuclear cells (Wertheim et al, 1993), and
inhibited that in human peripheral blood monocytes (Standiford et
al, 1992). Possibly, the amounts and/or balance of cAMP-
responsive transcriptional activators like cAMP response element
binding protein (CREB), and of repressors like inducible cAMP
early repressor, may differ with cell types (Gellersen et al, 1997).
Such difference may in¯uence the cAMP-mediated regulation of
IL-8 transcription. At least in human melanoma WM266-4, cAMP
may contribute to the constitutive IL-8 transcription. The
sequences between ±98 and ±62 bp in the 5¢-¯anking region may
confer cAMP-mediated transcription and may be the target for
ganglioside-induced repression. This region does not contain the
binding sites for CREB or activator protein-2, however (Mukaida
et al, 1989). It contains CCAAT/enhancer-binding protein (C/
EBP) element (±94 to ±81) (Mukaida et al, 1989), which mediates
the constitutive IL-8 transcription in colonic adenocarcinoma
Caco-2 (Wu et al, 1997). Thus cAMP may upregulate IL-8
transcription indirectly via C/EBP element. It is reported that
cAMP induces the synthesis of C/EBPb via CREB; C/EBPb
promoter contains two adjacent CREB sites (Niehof et al, 1997).
Cyclic AMP-activated PKA phosphorylates CREB and thus
enhances its transcriptional activity on C/EBPb promoter (Kwok
et al, 1994; Niehof et al, 1997). Cyclic AMP also promotes the
nuclear translocation of C/EBPb via PKA-mediated phosphoryl-
ation (Metz and Ziff, 1991; Chinery et al, 1997). The critical region
between ±98 and ±62 bp on IL-8 promoter also contains the
binding site for nuclear factor kB (NF-kB) (±80 to ±70) (Mukaida
et al, 1989). It is reported that PKA-mediated phosphorylation of
cytosolic NF-kB induces its nuclear translocation and thus
enhances its transcriptional activity on k-immunoglobulin light
chain genes (Shirakawa and Mizel, 1989). Recent studies reported
that DNA binding of NF-kB was constitutively enhanced in
melanoma compared to melanocytes (Meyskens et al, 1999), and
that NF-kB may contribute to the constitutive IL-8 transcription in
melanoma (Huang et al, 2000). Thus NF-kB may also be involved
in the cAMP-mediated transcriptional activation. Besides the two
transcriptional activators C/EBPb and NF-kB interact with each
other on the adjacent binding sites of IL-8 promoter and thus
synergistically enhance the transcriptional ef®cacy (Kunsch et al,
1994). It is thus hypothesized that cAMP may induce the
synergistic IL-8 transcription via either or both of the two factors.
WM266-4 cells appeared to proliferate by an autocrine loop of
IL-8 as their growth was greatly suppressed by anti-IL-8 antibody
(Fig 2). The previous reports also con®rmed the role of IL-8 as an
autocrine growth factor of melanoma and the correlation of its
expression with metastatic potential (Schadendorf et al, 1993; Luca
et al, 1997; Huang et al, 2000). Certain melanoma cell lines may
grow independently from IL-8, however. GD1b, GT1b, GQ1b, or
the other gangliosides may regulate the growth of such melanoma
cells by modulating the production of growth factors different from
IL-8, such as transforming growth factor a or b (Shih and Herlyn,
1993). Further studies should elucidate the growth-regulatory
effects of gangliosides on the other IL-8-independently growing
melanoma cell lines.
In this study, GD1b, GT1b, and GQ1b inhibited in vitro growth
of melanoma. Our results indicate that these gangliosides may be
useful for the treatment of patients with melanoma. Our experi-
ments were performed on a culture of melanoma alone, however,
and thus the results may be valid only in the in vitro limited settings.
Possibly, individual gangliosides may regulate the in vivo progres-
sion of melanoma comprehensively by diverse effects on adhesion,
motility, stroma formation, angiogenesis, or metastasis, in addition
to cell proliferation per se. Such in vivo regulation by gangliosides
may depend on the biologic responses of melanoma itself and host
cells such as endothelial cells, macrophages, lymphocytes, or
®broblasts, and on their mutual interaction. The biologic responses
to gangliosides differ with cell types (Alessandri et al, 1987), and
thus circumspection is required to evaluate the total effects of
gangliosides on in vivo tumor progression. The growth factors
produced by melanoma act on host cells and host cells in turn
produce various factors that regulate the functions of tumor cells
(Herlyn, 1990; Lazar-Molnar et al, 2000); melanoma produces
vascular endothelial growth factor, which stimulates the growth of
endothelial cells, whereas ®broblasts produce insulin-like growth
factor I, which stimulates the motility of melanoma (Shih and
Herlyn, 1993). Exogenous gangliosides may alter the above-
mentioned autocrine and/or paracrine growth factor production.
Recent studies report that complex gangliosides, especially GT1b,
promote angiogenesis; GT1b promoted the growth and motility of
endothelial cells in synergy with bFGF, prostaglandin E1, or tumor-
derived conditioned medium, whereas GM3 was angiostatic (Ziche
et al, 1989; De Cristan et al, 1990; Alessandri et al, 1992; 1997).
These results indicate that complex gangliosides may promote the
in vivo progression of melanoma via angiogenesis and thus appear to
contradict our results in this study. Among melanoma-derived
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angiogenic factors (Folkman and Shing, 1992), the production of
IL-8 in WM266-4 was inhibited by GD1b, GT1b, and GQ1b, and
that of bFGF and PDGF-AB was not altered by any gangliosides.
The previous study reported that exogenous GD3 enhanced the
secretion of vascular endothelial growth factor in human glioma
cells (Koochekpour et al, 1996). The induction of GM2, GM1, and
GD1a expression in experimental mouse brain tumor EPEN
resulted in the enhancement of vascular endothelial growth factor
gene expression in vivo (Manfredi et al, 1999). It is not known,
however, whether exogenous gangliosides may modulate the
production of the other angiogenic factors, such as transforming
growth factor a (Schreiber et al, 1986), and that of angiostatic
factors, such as angiostatin or endostatin (O'Reilly et al, 1994;
1997), and thus should further be elucidated. Exogenous ganglio-
sides may also alter the laminin or metalloproteinase production in
melanoma, as reported in glioma cells (Koochekpour et al, 1995;
Maidment et al, 1996). Gangliosides also affect the host immune
responses to melanoma; Grayson and Ladisch (1992) reported that
GM2 and GM3 suppressed the activity of human natural killer cells.
We are now studying whether GD1b, GT1b, or GQ1b can in vivo
inhibit or stimulate the invasion and/or metastasis of WM266-4
cells transplanted into athymic nude mice. Further studies should
also elucidate the growth-regulatory effects of gangliosides on
in vitro coculture of melanoma with stromal cells such as
macrophages, ®broblasts, and especially endothelial cells. In add-
ition to the exogenous administration of gangliosides, the genetic
remodeling of the ganglioside pro®le in melanoma may alter its
growth modality; transfection of sialidase cDNA into murine B16
melanoma decreased intracellular GM3 expression and pulmonary
metastasis (Tokuyama et al, 1997), and transfection of GM2/GD2
synthase cDNA into B16 induced GM2 expression and reduced c-
Fos expression and in vitro and in vivo growth rate (Tsurifune et al,
2000). The transfection of antisense vector against GD3 synthase
reduced GD3 expression and in vivo growth rate of rat F-11 neural
tumor cells (Zeng et al, 2000). In contrast, the transfection of N-
acetylgalactosaminyl transferase into EPEN experimental mouse
brain tumor enhanced GM2, GM1, and GD1a expression and
in vivo vascularization and tumor growth rate (Manfredi et al, 1999).
Similar approaches may be necessary for clarifying the mechanism
of tumor growth and planning the gene therapy of melanoma.
We thank Dr. Tomoo Tanase (Takara Gene Analysis Center) for the synthesis of
IL-8 promoter-CAT reporter plasmids.
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